COMP <GO>
STE vs ABBV // EV/EBITDA & P/E VALUATION
STERIS plc (Ireland) (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: STE 8
— ABBV 7
▲ EV/EBITDA & P/E VALUATION LEADER: STE
LAST: $227.12 (-2.16%) • MKT CAP: $22.63B
valuation
17.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.20% | 70.20% | -26.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.10% | 29.00% | -18.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 17.0x | 33.3x | -16.30 | STE | /valuation <GO> |
| Free Cash Flow Yield | 4.30% | 3.47% | +0.83 | STE | /fcf-yield <GO> |
| Operating Margin | 18.60% | 24.60% | -6.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 13.20% | 6.90% | +6.30 | STE | /net-margins <GO> |
| Revenue Growth (YoY) | 8.70% | 8.60% | +0.10 | STE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.07% | 2.27% | -1.20 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.40 | 5.33 | +0.07 | STE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | STE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | STE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 72.8 | -15.88 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.9x | 113.1x | -86.20 | STE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.63B | $513.86B | -$491.23B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STE REV | ABBV REV | STE GROSS % | ABBV GROSS % | STE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.94B | $61.16B | 44.2% | 70.2% | $972.4M | $17.82B |
| FY 2024 | $5.46B | $56.33B | 44.0% | 70.0% | $778.0M | $17.83B |
| FY 2023 | $5.14B | $54.32B | 44.0% | 44.0% | $742.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STE // BETA 1.08
ABBV // BETA 1.15